B+
Bull case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
CRBP
CorbusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The October company presentation confirms TEMPO-1 first-patient dosing and reports a 5% placebo-adjusted 12-week weight-loss result for CRB-913's 60 mg cohort. Additional obesity data and first-line oncology combination data provide distinct clinical opportunities.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -15.5.
What can break
CANYON-1 adverse-event discontinuations were 12.9% in the 60 mg cohort versus 4.5% on placebo; longer and larger studies are needed to assess tolerability. [#8-K-2026-10-15]
Momentum
2
Value
58
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $8.00 · Bear $1.80Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $34.03
Why
Momentum2 · Δ7d +0.2
Value58 · Δ7d -0.4
Sentiment72 · Δ7d -15.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -15.5.
Contradictions & invalidation
- • CANYON-1 adverse-event discontinuations were 12.9% in the 60 mg cohort versus 4.5% on placebo; longer and larger studies are needed to assess tolerability. [#8-K-2026-10-15]
- • CRB-701 combination efficacy, TEMPO-1 enrollment, and future regulatory outcomes remain execution risks. [#8-K-2026-10-15]
- • CANYON-1 is an early, short-duration study, and the 60 mg cohort had higher adverse-event discontinuation than placebo.
Catalyst clock
2026-11-17
Additional CANYON-1 data at ObesityWeek
Lead driver: Sentiment · See AI snapshot
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.5
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+16.7
Sentiment
72
45% active weight
Current posture
7d trendImproving
Δ7d
-15.5
Δ21d
-10.4
Why this grade
Composite grade B. Momentum 2.2 / Value 57.7 / Sentiment 72.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$78.33M
Beta
2.87
Shares Out
19.34M
P/E (TTM) · Derived
-0.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.79
Rev YoY
-100.0%
EPS YoY
+25.1%
Gross Margin
-
Op Margin
-
Net Debt
-$162.31M
Current Ratio
5.71
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data